Abstract
Asthma is a chronic obstructive respiratory disease characterised by bronchial inflammation. Its biological and clinical features have been widely explored and a number of pharmacological treatments are currently available. Currently several aspects of asthma pathophysiological background remain unclear, and this is represent a limitation for the traditional asthma phenotype approach. In this scenario, the identification of new molecular and clinical biomarkers may be helpful in order to better understand the disease, define specific diagnostic tools and highlight relevant novel targets for pharmacological treatments. Omics technologies offer innovative research tools for addressing the above mentioned goals. However, there is still a lot to do both in the fields of basic research and in the clinical application. Recently, genome-wide association studies, microRNAs and proteomics are contributing to enrich the available data for the identification of new asthma biomarkers. A precise approach to the patient with asthma, particularly with severe uncontrolled asthma, requires new and specific therapeutic targets, but also proper tools able to drive the clinician in tailoring the treatment. On the other hand, there is a need of predictors to treatment’s response, particularly in the field of biological drugs, whose sustainability implies a correct and precise selection of the patients. Translating acquired omics knowledge in clinical practice may address the unmet needs described above, but large-scale studies are required in order to confirm their relevance and effectiveness in daily practice. Thus in our opinion the application of omics is still lagging in the real-life setting.
Highlights
Several aspects of asthma heterogeneity both from a clinical and pathophysiological perspective remain still unclear
We have expanded the part on epigenomics and metabolomics as required
We have extended the part about other matrixes for metabolomics analysis according to the reviewer indication, including new references
Summary
2. Mauro Maniscalco , ICS MAUGERI Institute of Telese Terme, Telese Terme, Italy. Any reports and responses or comments on the article can be found at the end of the article. We have expanded the part on epigenomics and metabolomics as required. We entered other proteins (IgEs, serum periostin, blood eosinophil, FeNO, dipeptidyl peptidase 4) as required by Dr Maniscalco. We have extended the part about other matrixes for metabolomics analysis according to the reviewer indication, including new references
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
